While nivolumab did not improve PFS compared with platinum-based chemotherapy in untreated patients with advanced NSCLC with ≥5% PD-L1 expression [50], an additional analysis of this study showed that a PFS advantage of nivolumab over chemotherapy was observed in patients with high TMB [51]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.